Related Experiment Video
Updated: Jun 28, 2026
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Using a silver-coated polymeric substrate for the management of chronic ulcerations: the initial Mayo Clinic
Rusty A Moore1, David A Liedl, Sarah Jenkins
1Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA.
Background:
This retrospective observational study was designed to review the use of a silver-coated polymeric substrate on various types of chronic wounds at the Mayo Clinic in Rochester, Minnesota.
Methods:
The study was set in a community and referral multidisciplinary vascular wound clinic. The authors identified the first 112 patients treated with a silver dressing in the center. Of these, 15 were lost to follow-up or had incomplete data. Ninety-seven patients were included in the study. Thirty-seven of these 97 patients had multiple wounds; however, 1 wound per person was randomly chosen for analysis. The median age of these patients was 69 years. A wound was considered healed when the wound was completely epithelialized. Of the 97 wounds evaluated, the primary etiologies were as follows: 20 (20.6%) were neurotrophic, 24 (24.7%) were ischemic (arterial, arteriolar, or vasculitic), 20 (20.6%) were venous, 7 (7.2%) were traumatic, and 16 (16.5%) were multifactorial. The silver dressing was the primary wound care product on all wounds. Silverlon (Argentum LLC, Chicago, Illinois) was the silver dressing used for this study. The frequency of dressing changes and use of secondary dressings, to keep the wound moist, were based on the amount of drainage, debris, and slough on the wound. Data pertaining to patient demographics, risk factors, wound etiology, noninvasive arterial vascular studies, frequency of dressing changes, wound discomfort, wound size, and wound duration were collected by retrospective chart review.
Results:
Thirty-five of the 97 wounds (36.1%) healed. The 62 nonhealed wounds (63.9%) decreased in size by a median of 55.2%. Among the 68 patients who had reported discomfort before the study, 77.9% reported no change in discomfort, 17.7% reported increased pain, and 4.4% reported decreased pain.
Conclusion:
A silver-coated polymeric substrate (Silverlon) can be used as an effective primary wound care dressing in patients with active wounds.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:25Peptic Ulcer Disease III: Clinical Manifestations and Complications